Jill Fredrickson1,2, Natalie J Serkova3, Shelby K Wyatt4, Richard A D Carano4, Andrea Pirzkall2, Ina Rhee2, Lee S Rosen5, Alberto Bessudo6, Colin Weekes7, Alex de Crespigny1,2. 1. Clinical Imaging Group, Genentech, Inc., South San Francisco, California, USA. 2. Oncology Clinical Development, Genentech, Inc., South San Francisco, California, USA. 3. Department of Anesthesiology, University of Colorado Cancer Center, Aurora, Colorado, USA. 4. Department of Biomedical Imaging, Genentech, Inc., South San Francisco, California, USA. 5. Department of Medicine, Division of Hematology and Oncology, UCLA, Santa Monica, California, USA. 6. San Diego Pacific Oncology Hematology Associates Inc., Encinitas, California, USA. 7. Department of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA.
Abstract
PURPOSE: To assess the feasibility of acquiring vessel size imaging (VSI) metrics using ferumoxytol injections and stock pulse sequences in a multicenter Phase I trial of a novel therapy in patients with advanced metastatic disease. METHODS: Scans were acquired before, immediately after, and 48 h after injection, at screening and after 2 weeks of treatment. ΔR2 , ΔR2*, vessel density (Q), and relative vascular volume fractions (VVF) were estimated in both normal tissue and tumor, and compared with model-derived theoretical and experimental estimates based on preclinical murine xenograft data. RESULTS: R2 and R2* relaxation rates were still significantly elevated in tumors and liver 48 h after ferumoxytol injection; liver values returned to baseline by week 2. Q was relatively insensitive to changes in ΔR2*, indicating lack of dependence on contrast agent concentration. Variability in Q was higher among human tumors compared with xenografts and was mostly driven by ΔR2 . Relative VVFs were higher in human tumors compared with xenografts, while values in muscle were similar between species. CONCLUSION: Clinical ferumoxytol-based VSI is feasible using standard MRI techniques in a multicenter study of patients with lesions outside of the brain. Ferumoxytol accumulation in the liver does not preclude measurement of VSI parameters in liver metastases. Magn Reson Med 77:814-825, 2017.
PURPOSE: To assess the feasibility of acquiring vessel size imaging (VSI) metrics using ferumoxytol injections and stock pulse sequences in a multicenter Phase I trial of a novel therapy in patients with advanced metastatic disease. METHODS: Scans were acquired before, immediately after, and 48 h after injection, at screening and after 2 weeks of treatment. ΔR2 , ΔR2*, vessel density (Q), and relative vascular volume fractions (VVF) were estimated in both normal tissue and tumor, and compared with model-derived theoretical and experimental estimates based on preclinical murine xenograft data. RESULTS: R2 and R2* relaxation rates were still significantly elevated in tumors and liver 48 h after ferumoxytol injection; liver values returned to baseline by week 2. Q was relatively insensitive to changes in ΔR2*, indicating lack of dependence on contrast agent concentration. Variability in Q was higher among humantumors compared with xenografts and was mostly driven by ΔR2 . Relative VVFs were higher in humantumors compared with xenografts, while values in muscle were similar between species. CONCLUSION: Clinical ferumoxytol-based VSI is feasible using standard MRI techniques in a multicenter study of patients with lesions outside of the brain. Ferumoxytol accumulation in the liver does not preclude measurement of VSI parameters in liver metastases. Magn Reson Med 77:814-825, 2017.
Authors: James P B O'Connor; Alan Jackson; Geoff J M Parker; Caleb Roberts; Gordon C Jayson Journal: Nat Rev Clin Oncol Date: 2012-02-14 Impact factor: 66.675
Authors: Edit Dósa; Suchita Tuladhar; Leslie L Muldoon; Bronwyn E Hamilton; William D Rooney; Edward A Neuwelt Journal: Stroke Date: 2011-04-14 Impact factor: 7.914
Authors: Jason S Weinstein; Csanad G Varallyay; Edit Dosa; Seymur Gahramanov; Bronwyn Hamilton; William D Rooney; Leslie L Muldoon; Edward A Neuwelt Journal: J Cereb Blood Flow Metab Date: 2009-09-16 Impact factor: 6.200
Authors: Seymur Gahramanov; Ahmed M Raslan; Leslie L Muldoon; Bronwyn E Hamilton; William D Rooney; Csanad G Varallyay; Jeffrey M Njus; Marianne Haluska; Edward A Neuwelt Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-13 Impact factor: 7.038
Authors: Christoph Bremer; Mona Mustafa; Alex Bogdanov; Vasilis Ntziachristos; Alexander Petrovsky; Ralph Weissleder Journal: Radiology Date: 2003-01 Impact factor: 11.105
Authors: Deepak Sampath; Jason Oeh; Shelby K Wyatt; Tim C Cao; Hartmut Koeppen; Jeffrey Eastham-Anderson; Liliane Robillard; Calvin C K Ho; Jed Ross; Guanglei Zhuang; Hani Bou Reslan; Philip Vitorino; Kai H Barck; Sharon E Ungersma; Jean Michel Vernes; Maresa Caunt; Nick Van Bruggen; Weilan Ye; Ulka Vijapurkar; Yu-Ju Gloria Meng; Napoleone Ferrara; Lori S Friedman; Richard A D Carano Journal: Neoplasia Date: 2013-07 Impact factor: 5.715
Authors: P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff Journal: J Magn Reson Imaging Date: 1999-09 Impact factor: 4.813
Authors: Mirjam Gerwing; Tobias Krähling; Christoph Schliemann; Saliha Harrach; Christian Schwöppe; Andrew F Berdel; Sebastian Klein; Wolfgang Hartmann; Eva Wardelmann; Walter L Heindel; Georg Lenz; Wolfgang E Berdel; Moritz Wildgruber Journal: Cancers (Basel) Date: 2021-11-23 Impact factor: 6.639